In line with the pre-clinical data at CCIT-DK, we recently obtained impressive response and survival rates in metastatic melanoma by combining an immune modulatory peptide vaccine targeting IDO and PD-L1 with the CPI nivolumab in a phase I–II clinical trial (NCT03047928) (17). The gene discussed is IDO1; the disease is metastatic melanoma.